Condensed Statements of Shareholders' Deficiency - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Beginning balance (in shares)			1,899,575
Beginning balance	$ (1,180,299)	$ (1,059,842)	$ (1,153,602)	$ (1,035,129)
Net loss	$ (33,459)	(30,746)	$ (60,156)	(55,459)
Ending balance (in shares)	1,899,575		1,899,575
Ending balance	$ (1,213,758)	$ (1,090,588)	$ (1,213,758)	$ (1,090,588)
Common Stock
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Beginning balance (in shares)	1,899,575	1,899,575	1,899,575	1,899,575
Beginning balance	$ 1,900	$ 1,900	$ 1,900	$ 1,900
Ending balance (in shares)	1,899,575	1,899,575	1,899,575	1,899,575
Ending balance	$ 1,900	$ 1,900	$ 1,900	$ 1,900
Additional Paid-in Capital
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Beginning balance	8,418,684	8,418,684	8,418,684	8,418,684
Ending balance	8,418,684	8,418,684	8,418,684	8,418,684
Accumulated Deficit
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Beginning balance	(9,600,883)	(9,480,426)	(9,574,186)	(9,455,713)
Net loss	(33,459)	(30,746)	(60,156)	(55,459)
Ending balance	$ (9,634,342)	$ (9,511,172)	$ (9,634,342)	$ (9,511,172)